Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI 182780

Clinical Cancer Research

Volumn 2, Issue 12, 1996, Pages 2037-2042

  Huynh, Hung ^a   Nickerson, Tara ^a   Pollak, Michael ^a   Yang, Xiaofeng ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; FULVESTRANT; MESSENGER RNA; SOMATOMEDIN C RECEPTOR;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REGULATORY MECHANISM;

BREAST NEOPLASMS; CELL DIVISION; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH SUBSTANCES; HALF-LIFE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; IODINE RADIOISOTOPES; RECEPTOR, IGF TYPE 1; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0030458110     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Ullrich, A., Gray, A., Tam, A. W , Yang-Feng, T., Tsubokawa, M., Collins, C., Henzel, W., Le Bon, T., Kathuria, S., Chen, E., Jacobs, S., Francke, U., Ramachendran, J., and Fujita-Yamaguchi, Y. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J., 5, 2503-2512, 1986.
2. Clemmons, D. IGF binding proteins and their functions. Mol. Reprod. Dev., 35: 368-374, 1993.
3. Macaulay, V. M. Insulin-like growth factors and cancer. Br. J. Cancer, 65: 311-320, 1992.
4. Steller, M. A., Delgado, C. H., Bartels, C. J., Woodworth, C. D., and Zou, Z. Q. Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res., 56: 1761-1765, 1996.
5. Baserga, R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res., 55: 249-252, 1995.
6. Sell, C., Rubini, M., Rubin, R., Liu, J. P., Efstratiadis, A., and Baserga, R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl. Acad. Sci. USA, 90: 11217-11221, 1993.
7. Resnicoff, M., Sell, C , Rubini, M., Coppola, D., Ambrose, D., Baserga, R., and Rubin, R. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res., 54: 2218-2222, 1994.
8. Neuenschwander, S., Roberts, C. T., and LeRoith, D. Growth inhibition of MCF7 breast cancer cells by stable transfection of an IGF-I receptor antisense ribonucleic acid. Endocrinology, 136: 4298-4303, 1995.
9. Sell, C., Dumenil, G., Deveaud, C., Miura, M., Coppola, D., DeAngelis, T., Rubin, R., Efstratiadis, A., and Baserga, R. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol. Cell. Biol., 14: 3604-3612, 1994.
10. Coppola, D., Ferber, A., Miura, M., Sell, C., D'Ambrosio, C., Rubin, R., and Baserga, R. A functional insulin-like; growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol. Cell. Biol., 14: 4588-4595, 1994.
11. Baserga, R. Oncogenes and the strategy of growth factors. (Review). Cell, 79: 927-930, 1994.
12. Resnicoff, M., Abraham, D., Yutanawiboonchai, W., Rotman, H. L., Kajstura, J., Rubin, R., Zoltick, P., and Baserga, R. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res., 55: 2463-2469, 1995.
13. Kaleko, M., Rutter, W. J., and Miller, A. D. Overexpression of the human insulin-like growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol. Cell. Biol., 10: 464-473, 1990.
14. Pietrzkowski, Z., Lammers, R., Carpenter, G., Soderquist, A. M , Limardo, M., Phillips, P. D., Ullrich, A., and Baserga, R. Constitutive expression of IGF-1 and IGF-1 receptor abrogates all requirements for exogenous growth factors. Cell Growth & Differ., 3: 199-205, 1992.
15. Stewart, A. J., Johnson, M. D., May, F. E. B., and Westley, B. R. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J. Biol. Chem., 265: 21172-21178, 1990.
16. Wiseman, L. R., Johnson, M. D., Wakeling, A. E., Lykkesfeldt, A. E., Felicity, E B., Westley, M. R., and Westley, B. R. Type I IGF receptor and acquired tamoxifen resistance in estrogen-responsive human breast cancer cells. Eur. J. Cancer. 29A: 2256-2264, 1993.
17. Freiss, G., Rochefort, H , and Vignon, F. Mechanisms of 4-hydroxytamoxifen anti-growth factor activity in breast cancer cells: alterations of growth factor receptor binding sites and tyrosine kinase activity. Biochem. Biophys. Res. Commun., 173: 919-926, 1990.
18. Wakeling, A. E., Dukes, M., and Bowler, J. A potent specific pure antiestrogen with clinical potential. Cancer Res., 51: 3867-3873, 1991.
19. Huynh, H. T., Yang, X., and Pollak, M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J. Biol. Chem., 271-1016-1021, 1996.
20. Pratt, S., and Pollak, M. Insulin-like growth factor binding protein 3 inhibits estrogen-stimulated breast cancer cell proliferation. Biochem. Biophys. Res. Commun., 198: 292-297, 1994.
21. Huynh, H T., and Pollak, M. ICF-1 gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. Cancer Res., 53: 5585-5588, 1993.
22. Noda, M., Yoon, K., and Rodan, G. A. Cyclic AMP-mediated stabilization of osteocalcin mRNA in rat osteoblast-like cells treated with parathyroid hormone. J. Biol. Chem., 263: 18574-18577, 1988.
23. Ausubel, E. F., Brent, R., Kingston, R. E., Moore, D. D , Seidman, J. G., Smith, J. A., and Struhl, K. Current Protocols in Molecular Biology. New York, NY: Current Protocols, 1993.
24. Jakowlew, S. B., Breathnach, R., Jeltsch, J. M., Masiakowski, P., and Chambon, P. Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. Nucleic Acids Res., 12: 2861-2878, 1984.
25. Jeltsch, J. M., Roberts, M., Schatz, C., Garnier, J. M., Brown, A. M., and Chambon, P. Structure of the human oestrogen-responsive gene pS2. Nucleic Acids Res., 15: 1401-1414, 1987.
26. Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., Metzger, D., and Chambon, P. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science (Washington DC), 270: 1491-1494, 1995.
27. Huynh, H. T., Yang, X., and Pollak, M. A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780 Cell Growth & Differ., in press, 1996.
28. Osborne, C. K , Coronado, E. B., Kitten, L. J., Arteaga, C. L., Fuqua, S. A., Ramasharma, K., Marshall, M., and Li, C. H. Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol. Endocrinol., 3: 1701-1709, 1989.
29. Resnicoff, M., Burgaud, J. L., Rotman, H. L., Abraham, D., and Baserga, R. Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. Cancer Res., 55: 3739-3741, 1995.
30. Wilson, J. W., Wakeling, A. E., Morris, I. D., Hickman, J. A., and Dive, C. MCF-7 human mammary adenocarcinoma cell death in vitro in response to hormone-withdrawal and DNA damage. Int. J. Cancer, 61: 502-508, 1995.
31. Tannenbaum, G S., Gurd, W., Lapointe, M., and Pollak, M. Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. Endocrinology, 130: 3395-3401, 1992.
32. Pollak, M., Costantino, J., Polychronakos, C., Blauer, S., Guyda, H., Redmond, C., Fisher, B., and Margolese, R. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J. Natl. Cancer Inst., 82: 1693-1697, 1990.
33. Huynh, H. T., Tetenes, E., Wallace, L., and Pollak, M. In vivo inhibition of insulin-like growth factor-I gene expression by tamoxifen. Cancer Res., 53: 1727-1730, 1993.